Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-17-013301
Filing Date
2017-11-15
Accepted
2017-11-14 21:47:00
Documents
38
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 259832
2 ex1-1.htm EX-1.1 14358
3 ex2-1.htm EX-2.1 10109
  Complete submission text file 0001493152-17-013301.txt   1458773

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE oti-20170930.xml EX-101.INS 160196
5 XBRL SCHEMA FILE oti-20170930.xsd EX-101.SCH 22704
6 XBRL CALCULATION FILE oti-20170930_cal.xml EX-101.CAL 23861
7 XBRL DEFINITION FILE oti-20170930_def.xml EX-101.DEF 68298
8 XBRL LABEL FILE oti-20170930_lab.xml EX-101.LAB 161703
9 XBRL PRESENTATION FILE oti-20170930_pre.xml EX-101.PRE 117939
Mailing Address 233 NEEDHAM STREET SUITE 300 NEWTON MA 02464
Business Address 233 NEEDHAM STREET SUITE 300 NEWTON MA 02464 617-454-1199
Oxygen Therapy, Inc. (Filer) CIK: 0001685616 (see all company filings)

EIN.: 812723728 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 333-214306 | Film No.: 171203725
SIC: 2834 Pharmaceutical Preparations